Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accounts Payables (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Accounts Payables for 6 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 40.68% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 40.68% increase, with the full-year FY2024 number at $2.5 million, down 20.64% from a year prior.
  • Accounts Payables was $3.8 million for Q3 2025 at Caribou Biosciences, up from $3.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.9 million in Q1 2024 to a low of $426000.0 in Q2 2022.
  • A 5-year average of $2.9 million and a median of $2.9 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: crashed 71.28% in 2022, then soared 940.61% in 2023.
  • Caribou Biosciences' Accounts Payables stood at $4.0 million in 2021, then plummeted by 71.28% to $1.1 million in 2022, then surged by 172.25% to $3.1 million in 2023, then decreased by 20.64% to $2.5 million in 2024, then skyrocketed by 53.63% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Accounts Payables are $3.8 million (Q3 2025), $3.2 million (Q2 2025), and $3.9 million (Q1 2025).